S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
pixel
Log in
NASDAQ:NKTR

Nektar Therapeutics Stock Forecast, Price & News

$22.69
+0.25 (+1.11 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.23
Now: $22.69
$23.75
50-Day Range
$16.56
MA: $20.22
$25.46
52-Week Range
$13.63
Now: $22.69
$26.75
Volume1.74 million shs
Average Volume1.53 million shs
Market Capitalization$4.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:NKTR
CUSIP64026810
Phone415-482-5300
Employees723
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$114.62 million
Book Value$7.99 per share

Profitability

Net Income$-440,670,000.00
Net Margins-269.05%

Miscellaneous

Market Cap$4.07 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

371st out of 1,960 stocks

Pharmaceutical Preparations Industry

186th out of 771 stocks

Analyst Opinion: 3.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$22.69
+0.25 (+1.11 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

Is Nektar Therapeutics a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Nektar Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View analyst ratings for Nektar Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Nektar Therapeutics?

Wall Street analysts have given Nektar Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nektar Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Nektar Therapeutics
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) posted its quarterly earnings results on Thursday, February, 25th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.03. Nektar Therapeutics had a negative net margin of 269.05% and a negative trailing twelve-month return on equity of 30.74%. During the same quarter last year, the business earned ($0.64) earnings per share.
View Nektar Therapeutics' earnings history
.

How has Nektar Therapeutics' stock price been impacted by Coronavirus?

Nektar Therapeutics' stock was trading at $16.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NKTR stock has increased by 37.8% and is now trading at $22.69.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NKTR?

14 analysts have issued 12-month price targets for Nektar Therapeutics' shares. Their forecasts range from $18.00 to $80.00. On average, they expect Nektar Therapeutics' stock price to reach $30.67 in the next year. This suggests a possible upside of 35.2% from the stock's current price.
View analysts' price targets for Nektar Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the following people:
  • Mr. Howard W. Robin, CEO, Pres & Director (Age 68, Pay $1.19M)
  • Mr. Gilbert M. Labrucherie, Sr. VP, CFO & COO (Age 49, Pay $695.82k)
  • Ms. Jillian B. Thomsen, Sr. VP of Fin. & Chief Accounting Officer (Age 55, Pay $470.79k)
  • Dr. Jonathan Zalevsky, Chief R&D Officer (Age 46, Pay $590.12k)
  • Mr. John P. Northcott, Sr. VP & Chief Commercial Officer (Age 43, Pay $269.56k)
  • Mr. Mark A. Wilson, Sr. VP, Gen. Counsel & Sec.
  • Ms. Jennifer Ruddock, Sr. VP of Strategy & Corp. Affairs
  • Dr. Mary Tagliaferri, Sr. VP & Exec. Clinical Fellow (Age 55)
  • Dr. Brian L. Kotzin, Interim Chief Medical Officer & Head of Devel. (Age 71)
  • Dr. Kevin Brodbeck, Sr. VP of Manufacturing

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics CEO Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among Nektar Therapeutics' employees.

Who are some of Nektar Therapeutics' key competitors?

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (10.28%), BlackRock Inc. (10.24%), First Trust Advisors LP (2.13%), Bank of New York Mellon Corp (0.97%), Northern Trust Corp (0.77%) and Rhenman & Partners Asset Management AB (0.75%). Company insiders that own Nektar Therapeutics stock include Curet Myriam, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Mark Andrew Wilson, R Scott Greer, Robert Chess and Stephen K Doberstein.
View institutional ownership trends for Nektar Therapeutics
.

Which major investors are selling Nektar Therapeutics stock?

NKTR stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Credit Suisse AG, Price T Rowe Associates Inc. MD, Primecap Management Co. CA, Tudor Investment Corp Et Al, Bank of New York Mellon Corp, Northern Trust Corp, and JPMorgan Chase & Co.. Company insiders that have sold Nektar Therapeutics company stock in the last year include Curet Myriam, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jonathan Zalevsky, Mark Andrew Wilson, R Scott Greer, and Robert Chess.
View insider buying and selling activity for Nektar Therapeutics
or view top insider-selling stocks.

Which major investors are buying Nektar Therapeutics stock?

NKTR stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, BlackRock Inc., Rhenman & Partners Asset Management AB, Ieq Capital LLC, Engineers Gate Manager LP, Avoro Capital Advisors LLC, California Public Employees Retirement System, and US Bancorp DE.
View insider buying and selling activity for Nektar Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $22.69.

How much money does Nektar Therapeutics make?

Nektar Therapeutics has a market capitalization of $4.07 billion and generates $114.62 million in revenue each year. The biopharmaceutical company earns $-440,670,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

Nektar Therapeutics employs 723 workers across the globe.

What is Nektar Therapeutics' official website?

The official website for Nektar Therapeutics is www.nektar.com.

Where are Nektar Therapeutics' headquarters?

Nektar Therapeutics is headquartered at 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]


This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.